| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/28/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/10/2023 | 263.04% | HC Wainwright & Co. | $1 → $11 | Reiterates | → Buy |
| 10/26/2022 | -67% | HC Wainwright & Co. | $1.5 → $1 | Maintains | Buy |
| 08/29/2022 | -67% | HC Wainwright & Co. | $1.5 → $1 | Maintains | Buy |
| 05/02/2022 | -50.5% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 03/31/2022 | -33.99% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
What is the target price for Timber Pharmaceuticals (TMBR)?
The latest price target for Timber Pharmaceuticals (AMEX: TMBR) was reported by HC Wainwright & Co. on August 28, 2023. The analyst firm set a price target for $0.00 expecting TMBR to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Timber Pharmaceuticals (TMBR)?
The latest analyst rating for Timber Pharmaceuticals (AMEX: TMBR) was provided by HC Wainwright & Co., and Timber Pharmaceuticals downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Timber Pharmaceuticals (TMBR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Timber Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Timber Pharmaceuticals was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.
Is the Analyst Rating Timber Pharmaceuticals (TMBR) correct?
While ratings are subjective and will change, the latest Timber Pharmaceuticals (TMBR) rating was a downgraded with a price target of $0.00 to $0.00. The current price Timber Pharmaceuticals (TMBR) is trading at is $3.03, which is out of the analyst's predicted range.